ScreenerHero

ACOG Alpha Cognition Inc.

NAS · US · Healthcare · Biotechnology · alphacognition.com
9.040USD+0.67%Mkt Cap: 196.87M $P/E: —

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development pro…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap196.87M USD
Enterprise Value154.18M USD
Revenue (TTM)15.26M USD
Gross Profit8.30M USD
Net Income (TTM)-20.67M USD
Revenue/Share0.74 USD
Last Price9.040 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees71
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-14.48
PEG—
EV/EBITDA-5.82
EV/Revenue10.10
P/S12.81
P/B3.69
EPS (TTM)-1.30
EPS (Forward)-0.62
52W Range
4.50080% of range10.14
52W High10.14 USD
52W Low4.500 USD
Profitability
Gross Margin81.26%
Oper. Margin-127.29%
EBITDA Margin-173.57%
Profit Margin-202.24%
ROE-33.06%
ROA-25.92%
Growth
Revenue Growth267.60%
Earnings Growth—
Cash Flow & Leverage
Operating CF-20.38M USD
CapEx (TTM)293.49K USD
FCF Margin-186.95%
FCF Yield-14.49%
Net Debt-41.38M USD
Net Debt/EBITDA1.56
Balance Sheet
Debt/Equity—
Current Ratio9.03
Quick Ratio7.31
Book Value/Sh2.43 USD
Cash/Share1.90 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)18.00 USD
Upside (mean)+99.1%
Target Range12.00 USD – 21.00 USD
12.00+99.1% to mean21.00
# Analysts5
Ownership
Shares Out.21.78M
Float10.80M
Insiders5.13%
Institutions56.80%
Short Interest
Short Ratio1.3d
Short % Float1.21%
Short % Out.0.96%
Shares Short209.23K
Short (prev mo.)203.93K
Technical
SMA 508.951 (+1.0%)
SMA 2006.904 (+30.9%)
Beta2.23
S&P 52W Chg16.45%
Avg Vol (30d)119.24K
Avg Vol (10d)105.37K
Technical Indicators
RSI (14)52.8
MACD0.0118
MACD Signal-0.0216
MACD Hist.+0.0334
BB Upper9.230 USD
BB Middle8.820 USD
BB Lower8.411 USD
BB Width9.29%
ATR (14)0.5423 USD
Vol Ratio (20d)0.35x